Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors
anti-retroviral drugs, such as Pfizer's Selzentry therapy, which is the first in its class to be FDA approved, block the CCR5 co-receptor to inhibit disease progression.
We are also very grateful to NIAID scientists for including Samaritan's SP-10 in this study; and look forward to the further development of SP-10, as an oral entry inhibitor
, for HIV and HCV.
gain attention as a potential new class of antiretrovirals.
In addition, newer agents with novel mechanisms of action, such as HIV entry inhibitors
(which inhibit the three steps of HIV entry: CD4 attachment, chemokine co-receptor binding and membrane fusion) and HIV integrase inhibitors, are also under investigation.
There was a lot of data presented at the IAS conference on several new drugs in the entry inhibitor
class which are currently under study (commonly known as CCR5 antagonists or "blockers").
Two studies at the conference showed that when HIV is resistant to Fuzeon (an entry inhibitor
that is taken twice daily by injection under the skin), it may not be as strong as the natural (or "wild-type") virus.
The entry inhibitor
category includes the fusion inhibitor class, as well as two other classes: attachment inhibitors and co-receptor inhibitors.
The entry inhibitor
"pipeline" for treating HIV has just become more promising.
Fuzeon (aka T-20 or enfuvirtide) is a type of entry inhibitor
known as a fusion inhibitor.
Closest to Food and Drug Administration approval are drugs in the entry inhibitor
In some situations (especially if HIV drug resistance is a problem), these types of medications may be combined together in different ways, sometimes also including an entry inhibitor
Farther down the road, at least 2 new entry inhibitor
drugs will most likely become available at a similar time.
The mechanism of T-20 is well established in clinical trials and this agent is likely to be the first entry inhibitor
to gain US Food & Drug Administration (FDA) approval.
In the area of virology, Progenics is conducting phase 2 clinical trials of its HIV entry inhibitor
PRO 140, a humanized monoclonal antibody targeting the entry co-receptor CCR5.